MCID: CNJ013
MIFTS: 67

Conjunctivitis

Categories: Eye diseases, Nephrological diseases, Gastrointestinal diseases, Respiratory diseases, Cardiovascular diseases, Infectious diseases

Aliases & Classifications for Conjunctivitis

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 12 72 28 51 3 41 14 69 59
Madras Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6195
ICD10 32 H10 H10.9
ICD9CM 34 372.30
MeSH 41 D003231
NCIt 46 C34504
UMLS 69 C0009763

Summaries for Conjunctivitis

PubMed Health : 59
About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other.Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks.Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and papillary conjunctivitis, and has symptoms including discharge from eye, redness of eye and conjunctival congestion. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Oralair and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and immune system

CDC : 3 People often call conjunctivitis “pink eye” because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

Wikipedia : 72 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Related Diseases for Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 636)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 33.9 CCL11 CXCL8 IL4
2 papillary conjunctivitis 33.2 CCL11 CXCL8 IL4 IL6
3 chronic conjunctivitis 33.1 CCL11 IL13 IL4 IL5 RNASE3
4 vernal conjunctivitis 32.7 IFNG IL2 IL4 MS4A2 RNASE3
5 blepharoconjunctivitis 32.5 CCL11 IL4 RNASE3
6 measles 31.9 IFNG IL2 IL4
7 trichinosis 30.9 IL4 IL5
8 chlamydia 30.5 CXCL8 IFNG IL6
9 allergic conjunctivitis 30.4 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
10 pollen allergy 30.1 FOXP3 ICAM1 IL13 IL5 RNASE3
11 gingivitis 29.9 CXCL8 IL4 IL6
12 uveitis 29.7 ICAM1 IFNG IL4
13 viral infectious disease 29.7 CXCL8 IFNG IL2 IL4 IL6
14 hematopoietic stem cell transplantation 29.7 IFNG IL2 IL6
15 coccidiosis 29.6 IFNG IL2 IL4
16 sinusitis 29.5 CXCL8 IL5 RNASE3
17 necrotizing fasciitis 29.5 CXCL8 IL2 IL6
18 pneumonia 29.5 CCL11 CXCL8 IL13 IL5 IL6
19 myasthenia gravis 29.4 IFNG IL2 IL4
20 spondyloarthropathy 29.4 IFNG IL2 IL4 IL6
21 bullous pemphigoid 29.3 CCL11 IL5 RNASE3
22 dermatitis 29.3 CCL11 IFNG IL13 IL4 IL5 RNASE3
23 lymphopenia 29.2 FOXP3 IFNG IL2
24 otitis media 29.2 CCL11 CXCL8 IL4 IL6 RNASE3
25 poliomyelitis 29.2 ICAM1 IFNG IL4
26 wegener granulomatosis 29.2 CXCL8 IFNG IL6
27 urticaria 29.2 HRH1 MS4A2 NLRP3 RNASE3
28 meningitis 29.1 CXCL8 IFNG IL6 NLRP3
29 lichen planus 29.1 ICAM1 IFNG IL4
30 periodontitis 29.1 CXCL8 IFNG IL4 IL6
31 interstitial lung disease 29.1 CXCL8 IFNG IL4 IL6
32 mastitis 29.1 CXCL8 ICAM1 IL6
33 synovitis 29.0 CXCL8 ICAM1 IL6
34 vernal keratoconjunctivitis 29.0 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
35 allergic rhinitis 28.8 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
36 atopic keratoconjunctivitis 28.8 IFNG IL2 IL4 IL5 RNASE3
37 renal cell carcinoma, nonpapillary 28.7 ICAM1 IFNG IL2 IL4
38 peritonitis 28.7 CXCL8 ICAM1 IFNG IL6
39 rhinitis 28.4 CCL11 CXCL8 HRH1 ICAM1 IL13 IL4
40 ige responsiveness, atopic 28.4 IFNG IL13 IL4 IL5 MS4A2 RNASE3
41 allergic hypersensitivity disease 28.1 CCL11 HRH1 IFNG IL13 IL4 IL5
42 autoimmune disease 28.1 FOXP3 IFNG IL2 IL4 IL5 IL6
43 contact dermatitis 28.1 CXCL8 ICAM1 IFNG IL4 IL5 IL6
44 rheumatoid arthritis 27.9 CXCL8 FOXP3 ICAM1 IFNG IL2 IL4
45 keratoconjunctivitis 27.9 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
46 systemic lupus erythematosus 27.9 FOXP3 ICAM1 IFNG IL2 IL4 IL6
47 upper respiratory tract disease 27.0 CCL11 CXCL8 HRH1 IL13 IL33 IL4
48 dermatitis, atopic 26.7 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
49 asthma 26.4 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
50 inflammatory bowel disease 26.4 CCL11 CXCL8 FOXP3 ICAM1 IFNG IL13

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis

Symptoms & Phenotypes for Conjunctivitis

UMLS symptoms related to Conjunctivitis:


discharge from eye, redness of eye, conjunctival congestion, bloodshot eye

MGI Mouse Phenotypes related to Conjunctivitis:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 HRH1 IL13 ICAM1 CCL11 FOXP3 IFNG
2 immune system MP:0005387 10.28 HRH1 IL13 ICAM1 CCL11 FOXP3 IFNG
3 digestive/alimentary MP:0005381 10.26 IL13 ICAM1 FOXP3 IFNG IL6 IL4
4 cellular MP:0005384 10.24 ICAM1 FOXP3 IFNG IL33 IL13 IL4
5 growth/size/body region MP:0005378 10.24 HRH1 IL13 ICAM1 FOXP3 IFNG IL5
6 homeostasis/metabolism MP:0005376 10.23 HRH1 IL13 ICAM1 FOXP3 IFNG IL33
7 endocrine/exocrine gland MP:0005379 10.16 IL13 ICAM1 FOXP3 IFNG IL33 IL6
8 integument MP:0010771 10.06 IL13 ICAM1 FOXP3 IFNG IL33 IL6
9 mortality/aging MP:0010768 10.06 IFNG HRH1 ICAM1 FOXP3 IL33 IL13
10 liver/biliary system MP:0005370 10.02 HRH1 FOXP3 IFNG IL6 IL4 IL2
11 reproductive system MP:0005389 9.85 IL13 FOXP3 IFNG IL33 IL6 IL4
12 neoplasm MP:0002006 9.73 ICAM1 IFNG IL5 IL2 PLG IL6
13 respiratory system MP:0005388 9.65 IL13 CCL11 FOXP3 IFNG IL33 IL6
14 vision/eye MP:0005391 9.17 IFNG ICAM1 FOXP3 IL4 IL2 PLG

Drugs & Therapeutics for Conjunctivitis

PubMedHealth treatment related to Conjunctivitis: 59

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection, even though conjunctivitis is more commonly caused by viruses. But antibiotics are only effective against bacteria, and have no effect on viruses. If the infection is viral, only the symptoms can be treated.Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful.If conjunctivitis is caused by an allergy, it can be treated with allergy medicine such as antihistamines.

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Oralair 17 Greer Labs April 2014

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
2
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
3
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
4
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
5
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
6
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2 56-81-5 753
7
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
8
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
9
Iodine Approved, Investigational Phase 4,Phase 3 7553-56-2 807
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 36294 5496
12
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
13
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
14
Loteprednol Approved Phase 4,Phase 3,Phase 2 129260-79-3, 82034-46-6 9865442 444025
15
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
16
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
17
Pheniramine Approved Phase 4 86-21-5 4761
18
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
19
Povidone Approved Phase 4,Phase 3 9003-39-8
20
Ethanol Approved Phase 4,Phase 2 64-17-5 702
21
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
22
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
23
Montelukast Approved Phase 4 158966-92-8 5281040
24
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 46936176 6474909
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
26
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-13-7, 34580-14-8 3827
27
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 53477736 447043 55185
28
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
29
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
30
Tranilast Approved, Investigational Phase 4 53902-12-8 93543
31
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
32
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
33
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
34
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
35
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
36
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 151096-09-2, 354812-41-2 152946
37
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
38
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
39
Menthol Approved Phase 4 2216-51-5 16666
40
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
41
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
42
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
43
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
44
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
45
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
46
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
47 Racepinephrine Approved Phase 4 329-65-7
48
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
49
Dimenhydrinate Approved Phase 4 523-87-5 441281
50
Sorbitol Approved Phase 4 50-70-4 5780

Interventional clinical trials:

(show top 50) (show all 828)

# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
5 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
6 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
7 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
8 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
9 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
11 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
12 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
13 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
14 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
15 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
16 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
17 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
18 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
19 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
20 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
21 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
22 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
23 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
24 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
25 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
26 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
27 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
28 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
29 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
30 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
31 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
32 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
33 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
34 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
35 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
36 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
37 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Artificial tears
38 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
39 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
40 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
41 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
42 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
43 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Completed NCT02256553 Phase 4 Rescue Medication
44 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
45 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
46 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
47 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
48 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
49 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
50 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: conjunctivitis

Genetic Tests for Conjunctivitis

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 28

Anatomical Context for Conjunctivitis

MalaCards organs/tissues related to Conjunctivitis:

38
Eye, Testes, Skin, T Cells, Thyroid, Bone, Prostate

Publications for Conjunctivitis

Articles related to Conjunctivitis:

(show top 50) (show all 1925)
# Title Authors Year
1
Conjunctivitis Occurring in Atopic Dermatitis Patients Treated with Dupilumab - Clinical Characteristics and Treatment. ( 29432961 )
2018
2
Costs of Conjunctivitis Outbreak, RAcunion Island, France. ( 29260662 )
2018
3
Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management. ( 29380707 )
2018
4
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with demodex and increased IL-17 levels? ( 29333603 )
2018
5
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression. ( 29398596 )
2018
6
Therapeutic and Analgesic Efficacy of Laser in Conjunction With Pharmaceutical Therapy for Trigeminal Neuralgia. ( 29399314 )
2018
7
The role of previous falls in major osteoporotic fracture prediction in conjunction with FRAX in older Chinese men and women: the Mr. OS and Ms. OS cohort study in Hong Kong. ( 29067485 )
2018
8
Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. ( 29432811 )
2018
9
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors. ( 29336016 )
2018
10
Fuchs syndrome: a case of fever, mucositis and conjunctivitis. ( 29378740 )
2018
11
Conjunctivitis, mucosal erosions, and moist cutaneous plaques. ( 29349113 )
2018
12
Tear osteopontin level and its relationship with local Th1/Th2/Th17/Treg cytokines in children with allergic conjunctivitis. ( 29279263 )
2018
13
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ( 29416652 )
2018
14
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. ( 29392313 )
2018
15
Aetiology of neonatal conjunctivitis evaluated in a population-based setting. ( 29345007 )
2018
16
Clinical Age-Specific Seasonal Conjunctivitis Patterns and Their Online Detection in Twitter, Blog, Forum, and Comment Social Media Posts. ( 29450538 )
2018
17
Role of enhanced receptor engagement in the evolution of a pandemic acute hemorrhagic conjunctivitis virus. ( 29284752 )
2018
18
Orthodontic Treatment in Conjunction with Twin-bock Treatment and Growth Hormone Therapy in Silver Russell Syndrome. ( 28872989 )
2017
19
Epidemiology of Conjunctivitis in US Emergency Departments. ( 28910427 )
2017
20
Treatment of Acute Conjunctivitis in the United States and Evidence of Antibiotic Overuse: Isolated Issue or a Systematic Problem? ( 28734327 )
2017
21
Eyelid Molluscum Contagiosum Lesions in Two Patients with Unilateral Chronic Conjunctivitis. ( 28845328 )
2017
22
Dynamic modelling of strategies for the control of acute haemorrhagic conjunctivitis outbreaks in schools in Changsha, China (2004-2015). ( 27758731 )
2017
23
Air pollution and outpatient visits for conjunctivitis: A case-crossover study in Hangzhou, China. ( 28947318 )
2017
24
Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece. ( 28428968 )
2017
25
Increased red cell distribution width levels in children with seasonal allergic conjunctivitis. ( 28523524 )
2017
26
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment. ( 29026285 )
2017
27
Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. ( 28593244 )
2017
28
Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study. ( 28630085 )
2017
29
Sensitization from ketotifen fumarate in eye drops presenting as chronic conjunctivitis. ( 28095628 )
2017
30
Follicular Conjunctivitis due to Chlamydia felis-Case Report, Review of the Literature and Improved Molecular Diagnostics. ( 28770201 )
2017
31
Ocular sporotrichosis: A frequently misdiagnosed cause of granulomatous conjunctivitis in epidemic areas. ( 29260114 )
2017
32
Diagnosis and management of allergic conjunctivitis in pediatric patients. ( 28052798 )
2017
33
More Than Meets the Eye: Adenoviral Conjunctivitis in Healthcare Settings. ( 28874219 )
2017
34
Conjunctivitis, Neonatal ( 28722870 )
2017
35
Conjunctivitis, Viral ( 29262100 )
2017
36
Rare case of pulmonary lymphomatoid granulomatosis in conjunction with tuberculosis: A case report. ( 29049243 )
2017
37
An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis. ( 28246054 )
2017
38
Clinical implications of mast cell involvement in allergic conjunctivitis. ( 29105783 )
2017
39
vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins. ( 28551640 )
2017
40
A rare case of methicillin resistant Staphylococcus aureus (MRSA) cerebral abscess secondary to conjunctivitis. ( 28733571 )
2017
41
Correction: Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28245290 )
2017
42
Angiolymphoid Hyperplasia with Eosinophilia Accompanying Vernal Conjunctivitis. ( 27993267 )
2017
43
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. ( 28652694 )
2017
44
Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice. ( 28676431 )
2017
45
Superoxide dismutase 3 attenuates experimental Th2-driven allergic conjunctivitis. ( 28063939 )
2017
46
Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. ( 28708424 )
2017
47
Patient demographic and microbiology trends in bacterial conjunctivitis in children. ( 29247795 )
2017
48
Pathogenesis, Transmissibility, and Tropism of a Highly Pathogenic Avian Influenza A(H7N7) Virus Associated With Human Conjunctivitis in Italy, 2013. ( 28934452 )
2017
49
An outbreak of acute haemorrhagic conjunctivitis associated with coxsackievirus A24 variant in The Gambia, West Africa. ( 29208044 )
2017
50
Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. ( 28007090 )
2017

Variations for Conjunctivitis

Expression for Conjunctivitis

Search GEO for disease gene expression data for Conjunctivitis.

Pathways for Conjunctivitis

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
2
Show member pathways
13.64 CCL11 CXCL8 IFNG IL13 IL2 IL4
3
Show member pathways
13.55 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
4
Show member pathways
13.4 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
5
Show member pathways
13.39 CCL11 CXCL8 IL13 IL2 IL4 IL5
6
Show member pathways
13.29 CCL11 CXCL8 IL13 IL2 IL4 IL5
7 12.9 CXCL8 IFNG IL13 IL2 IL4 IL5
8
Show member pathways
12.76 CXCL8 ICAM1 IFNG IL13 IL2 IL33
9
Show member pathways
12.69 FOXP3 IFNG IL13 IL2 IL4 IL5
10
Show member pathways
12.56 IFNG IL2 IL6 PLG
11
Show member pathways
12.56 IL13 IL4 IL5 MS4A2
12 12.54 FOXP3 IFNG IL2 IL4
13
Show member pathways
12.51 CXCL8 IFNG IL2 IL6
14
Show member pathways
12.5 ICAM1 IFNG IL2 IL4
15
Show member pathways
12.47 IFNG IL2 IL4 IL5 IL6
16
Show member pathways
12.47 CCL11 CXCL8 FOXP3 ICAM1 IFNG IL13
17
Show member pathways
12.46 IFNG IL13 IL2 IL4 IL5 IL6
18
Show member pathways
12.42 ICAM1 IFNG IL2 IL4 IL6 PLG
19
Show member pathways
12.4 CCL11 CXCL8 IFNG IL13 IL4 IL5
20
Show member pathways
12.26 CCL11 CXCL8 IFNG IL4 IL6
21
Show member pathways
12.16 CXCL8 IFNG IL13 IL2 IL4 IL5
22 12.11 CXCL8 ICAM1 IFNG IL2 IL4 IL6
23 12.09 IFNG IL2 IL4 IL5 IL6
24 12.07 CCL11 CXCL8 ICAM1 IL13 IL4 IL6
25
Show member pathways
11.96 IFNG IL2 IL4
26 11.92 CXCL8 IFNG IL6
27
Show member pathways
11.92 CXCL8 FOXP3 ICAM1 IL6
28
Show member pathways
11.91 IFNG IL2 IL6
29 11.91 CXCL8 ICAM1 IFNG IL6
30 11.89 CXCL8 ICAM1 IL6
31 11.88 IL4 IL5 IL6
32 11.87 CXCL8 IFNG IL6
33 11.87 IFNG IL13 IL2 IL33 IL4 IL5
34
Show member pathways
11.84 IFNG IL4 IL6
35
Show member pathways
11.84 CXCL8 FOXP3 IFNG IL2 IL4 IL5
36 11.82 CXCL8 IFNG IL6
37 11.8 FOXP3 ICAM1 IL4 IL5 IL6
38
Show member pathways
11.77 CXCL8 ICAM1 IFNG IL2 IL6
39 11.76 CXCL8 IL6 NLRP3
40 11.74 IFNG IL2 IL6
41 11.71 CCL11 CXCL8 IL13 IL4 IL5 IL6
42
Show member pathways
11.7 FOXP3 IL2 IL4
43 11.67 CCL11 IL4 IL5
44 11.67 CXCL8 ICAM1 IFNG IL13 IL2 IL4
45 11.66 CXCL8 ICAM1 IL13 IL4 IL6
46 11.63 CXCL8 ICAM1 IFNG IL6
47 11.61 CXCL8 IFNG IL6
48 11.57 IFNG IL2 IL6
49 11.54 ICAM1 IL6 PLG
50 11.5 CXCL8 ICAM1 IFNG

GO Terms for Conjunctivitis

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CCL11 CXCL8 IFNG IL13 IL2 IL33
2 extracellular space GO:0005615 9.4 CCL11 CXCL8 ICAM1 IFNG IL13 IL2

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.84 IFNG IL33 IL6 NLRP3
2 response to ethanol GO:0045471 9.83 ICAM1 IL13 IL2
3 response to virus GO:0009615 9.83 CCL11 FOXP3 IFNG
4 defense response to Gram-positive bacterium GO:0050830 9.82 IL6 NLRP3 RNASE3
5 negative regulation of inflammatory response GO:0050728 9.81 FOXP3 IL2 NLRP3
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 ICAM1 IL5 IL6
7 cellular response to lipopolysaccharide GO:0071222 9.8 CXCL8 ICAM1 IL6 NLRP3
8 movement of cell or subcellular component GO:0006928 9.79 CXCL8 IFNG IL13
9 cellular response to interleukin-1 GO:0071347 9.77 CCL11 CXCL8 ICAM1
10 positive regulation of T cell proliferation GO:0042102 9.76 IL2 IL4 IL6
11 inflammatory response GO:0006954 9.76 CCL11 CXCL8 HRH1 IL13 IL5 IL6
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 IFNG IL13 IL2 IL6
13 positive regulation of T cell differentiation GO:0045582 9.66 IL2 IL4
14 positive regulation of macrophage activation GO:0043032 9.65 IL13 IL33
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 ICAM1 IL13 IL4
16 negative regulation of interleukin-17 production GO:0032700 9.63 FOXP3 IFNG
17 positive regulation of interleukin-4 production GO:0032753 9.63 FOXP3 IL33 NLRP3
18 positive regulation of regulatory T cell differentiation GO:0045591 9.62 FOXP3 IL2
19 positive regulation of B cell proliferation GO:0030890 9.62 IL13 IL2 IL4 IL5
20 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL2 IL4
21 eosinophil chemotaxis GO:0048245 9.61 CCL11 HRH1
22 regulation of regulatory T cell differentiation GO:0045589 9.61 FOXP3 IFNG IL2
23 immune response GO:0006955 9.61 CCL11 CXCL8 IFNG IL13 IL2 IL4
24 positive regulation of interleukin-5 production GO:0032754 9.59 IL33 NLRP3
25 negative regulation of lymphocyte proliferation GO:0050672 9.58 FOXP3 IL2
26 positive regulation of type 2 immune response GO:0002830 9.57 IL33 NLRP3
27 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.56 IL6 NLRP3
28 positive regulation of immunoglobulin secretion GO:0051024 9.56 IL2 IL33 IL5 IL6
29 type 2 immune response GO:0042092 9.55 IL33 IL4
30 positive regulation of interleukin-13 production GO:0032736 9.54 IL33 IL4 NLRP3
31 negative regulation of T-helper 17 cell differentiation GO:2000320 9.52 FOXP3 IL2
32 negative regulation of complement-dependent cytotoxicity GO:1903660 9.51 IL13 IL4
33 regulation of receptor activity GO:0010469 9.28 CCL11 CXCL8 IFNG IL13 IL2 IL33
34 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 FOXP3 IL2 IL33 IL4 IL6 NLRP3

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 CCL11 CXCL8 IFNG IL13 IL2 IL33
2 growth factor activity GO:0008083 9.26 IL2 IL4 IL5 IL6

Sources for Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA